Conservative versus invasive strategy in elderly patients with non-ST-elevation myocardial infarction: insights from the international POPular age registry

This registry assessed the impact of conservative and invasive strategies on major adverse clinical events (MACE) in elderly patients with non-ST-elevation myocardial infarction (NSTEMI). Patients aged ≥75 years with NSTEMI were prospectively registered from European centers and followed up for one year. Outcomes were compared between conservative and invasive groups in the overall population and a propensity score-matched (PSM) cohort. MACE included cardiovascular death, acute coronary syndrome, and stroke. The study included 1190 patients (median age 80 years, 43% female). CAG was performed in 67% (N = 798), with two-thirds undergoing revascularization. Conservatively treated patients had higher baseline risk. After propensity score matching, 319 patient pairs were successfully matched. MACE occurred more frequently in the conservative group (total population 20% vs. 12%, adjHR 0.53, 95% CI 0.37–0.77, p = 0.001), remaining significant in the PSM cohort (18% vs. 12%, adjHR 0.50, 95% CI 0.31–0.81, p = 0.004). In conclusion, an early invasive strategy was associated with benefits over conservative management in elderly patients with NSTEMI. Risk factors associated with ischemia and bleeding should guide strategy selection rather than solely relying on age

A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure: Design and rationale of the MONITOR HF multicentre randomised clinical trial

Background: Assessing haemodynamic congestion based on filling pressures instead of clinical congestion can be a way to further improve quality of life (QoL) and clinical outcome by intervening before symptoms or weight gain occur in heart failure (HF) patients. The clinical efficacy of remote monitoring of pulmonary artery (PA) pressures (CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated in the USA. Currently, the PA sensor is not reimbursed in the European Union as its benefit when applied in addition to standard HF care is unknown in Western European countries, including the Netherlands. Aims: To demonstrate the efficacy and cost-effectiveness of haemodynamic PA monitoring in addition to contemporary standard HF care in a high-quality Western European health care system. Methods: The current study is a prospective, multi-centre, randomised clinical trial in 340 patients with chronic HF (New York Heart Association functional class III) randomised to HF care including remote monitoring with the CardioMEMS PA sensor or standard HF care alone. Eligible patients have at least one hospitalisation for HF in 12 months before enrolment and will be randomised in a 1:1 ratio. Minimum follow-up will be 1 year. The primary endpoint is the change in QoL as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Secondary endpoints are the number of HF hospital admissions and changes in health status assessed by EQ-5D-5L questionnaire including healt

Red cell dynamics and haemodynamics in cardiorenal failure

The combination of chronic heart failure (CHF) and chronic kidney disease (CKD) is prevalent and associated with a higher mortality and morbidity than can be expected solely on the combination of both conditions. This combination leads to a “dangerous liaison”, also called the cardiorenal syndrome, in which failure of the one organ accelerates the progression of structural damage and failure of the other organ. The responsible pathophysiological interactions that couple CHF and CKD are still incompletely identified. These underlying pathophysiological mechanisms can be differentiated in non-haemodynamic and haemodynamic interactions between heart and kidney. This thesis addressed red cell dynamics, the production and decay of the circulating erythrocyte, regarding the non-haemodynamic coupling. The important role of red cell dynamics shows by the high prevalence of anaemia. Potential causative mechanisms affect the erythropoiesis, such as an impaired erythropoietin (EPO) production, a disordered iron metabolism and a decreased responsiveness of the bone marrow for EPO (EPO resistance). Other causative mechanisms affect the life span of the red cell, such as inflammation. In this thesis we investigated the role of erythropoietin, focused on the differentiation between its erythropoietic and its non-erythropoietic effects. For this purpose we designed the EPOCARES study (the role of Erytropoietin in the CArdioREnal Syndrom), in which chronic, stable, ambulant patients with both CHF and CKD with a mild anaemia under oral iron supplementation were randomised into three groups. One group received a low fixed EPO dose to increase the haemoglobin level. The second group also received a low fixed EPO dose, but the haemoglobin levels in these patients were maintained at baseline level by sequential blood withdrawal. The third group received no EPO (control group). Data from this trial are used to address questions in this thesis. We demonstrate that only those patients whose haemoglobin level was let to increase experienced an improved quality of life and cardiac function. Moreover, we show a negative association between a measurement of heterogeneity in circulating red cells (RDW), which is associated with adverse prognosis, with quality of life and physical fitness. This association seems to be determined by functional iron availability, red cell turnover and inflammation. Hence, the positive effects of a low, fixed dose of ESA on cardiac function and quality of life in cardiorenal patients is dependent upon red cell levels, given the fact that there was no improvement in the phlebotomy group. Together with the negative correlation between RDW and quality of life this underscores the central role of red cell dynamics in cardiorenal patients. Regarding the haemodynamic coupling between heart and kidney failure we addressed atherosclerotic renal artery stenosis (ARAS) and stabilization of glomerular filtration rate (GFR) upon changes in blood pressure. We found a prevalence of 57% of ARAS in cardiorenal failure and this was not associated with cardiac function or the presence and extent of myocardial fibrosis. Furthermore, we only found a very weak association between changes in blood pressure and stabilization of GFR, even in the presence of ARAS